Eng
Es
It
Sp
For people exposed to radioactive material released during a radiation incident
Potassium Iodide (KI) tablets may help prevent thyroid cancer in people exposed to radioactive material released during a radiation incident. The thyroid gland is the part of the body that is most sensitive to radioactive iodine. KI tablets do not prevent any other radiation-related cancers. Because radiation-induced thyroid cancers are slow-growing, sometimes taking years to develop, KI tablets may be most effective for children and young adults.
People should only take KI (potassium iodide) on the advice of public health officials during an active incident.
While KI is good at preventing thyroid cancer when exposed to radiation, there are still risks you should be aware of, as with all medication. The risks of KI are the following:
If you are experiencing any of these side effects, please contact your doctor as soon as possible.
The St. Mary’s County Health Department (SMCHD) routinely distributes KI tablets to county residents living or working within the 10-mile emergency protection zone (EPZ) of the Calvert Cliffs Nuclear Power Plant to have on hand in case of emergency.
St. Mary’s County Residents living or working within the 10-mile EPZ (6 & 7). This area includes the following zip codes:
Potassium Iodide (KI) tablets will be routinely offered to eligible community members. The St. Mary’s County Health Department will issue a notice when the next distribution event is scheduled.
To make an appointment for pick-up at the SMCHD main office in Leonardtown, please email smchd.dpr@maryland.gov.
The following recommendations are for general information purposes. People should only take KI (potassium iodide) on the advice of public health or emergency management officials during an active incident. Click here for the SMCHD Informational Brochure on when and how to take KI (En Español).
In the case of an emergency incident, the community will be notified by the St. Mary’s County Government and St. Mary’s County Health Department via the CodeRED Emergency Notification System as well as through local news, radio, and social media outlets.
A single dose of KI (potassium iodide) protects the thyroid gland for 24 hours. A one-time dose at recommended levels is usually all that is needed to protect the thyroid gland. In some cases, people can be exposed to radioactive iodine for more than 24 hours. If that happens, public health or emergency management officials may tell you to take one dose of KI (potassium iodide) every 24 hours for a few days.
Infants have the highest risk of getting thyroid cancer after being exposed to radioactive iodine.
When recommended by public health/emergency officials, all children who are internally contaminated (or likely to be) with radioactive iodine should take the recommended dose of KI unless they have known allergies to iodine.
When recommended by public health/emergency officials, adults between the ages of 18 and 40 who are internally contaminated (or likely to be) with radioactive iodine should take the recommended dose of KI. Young adults are less sensitive to the effects of radioactive iodine than children.
Because all forms of iodine cross the placenta, pregnant women should take KI during an active incident to protect the growing fetus. Pregnant women who are internally contaminated, or likely to be, should take only one dose of recommended KI for adults.
Women who are breastfeeding and who are internally contaminated or likely to be, should take only one dose of recommended KI for adults.
Generally, adults older than 40 years should not take KI. Public health/emergency officials may recommend KI for this group if the emergency event/contamination of radioactive iodine is expected to be severe.
Consult your veterinarian before giving your pet Potassium Iodide (KI), keeping the following in mind:
For more information, please contact your veterinarian.
Mon – Fri: 8:00 am – 5:00 pm
Mon – Fri: 8:30 am – 4:00 pm
Mon & Thurs: 7:00 am – 2:00 pm
Tues, Wed, & Fri: 7:00 am – 4:30 pm
Enter your email to subscribe to the SMCHD newsletter and receive notifications of new health-related information.